GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alexion Pharmaceuticals Inc (NAS:ALXN) » Definitions » Return-on-Tangible-Asset

Alexion Pharmaceuticals (Alexion Pharmaceuticals) Return-on-Tangible-Asset : 24.82% (As of Mar. 2021)


View and export this data going back to 1996. Start your Free Trial

What is Alexion Pharmaceuticals Return-on-Tangible-Asset?

Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Alexion Pharmaceuticals's annualized Net Income for the quarter that ended in Mar. 2021 was $2,544 Mil. Alexion Pharmaceuticals's average total tangible assets for the quarter that ended in Mar. 2021 was $10,251 Mil. Therefore, Alexion Pharmaceuticals's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2021 was 24.82%.

The historical rank and industry rank for Alexion Pharmaceuticals's Return-on-Tangible-Asset or its related term are showing as below:

ALXN' s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: 1.58   Med: 11.58   Max: 33.36
Current: 7.05

During the past 13 years, Alexion Pharmaceuticals's highest Return-on-Tangible-Asset was 33.36%. The lowest was 1.58%. And the median was 11.58%.

ALXN's Return-on-Tangible-Asset is not ranked
in the Biotechnology industry.
Industry Median: -39.95 vs ALXN: 7.05

Alexion Pharmaceuticals Return-on-Tangible-Asset Historical Data

The historical data trend for Alexion Pharmaceuticals's Return-on-Tangible-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alexion Pharmaceuticals Return-on-Tangible-Asset Chart

Alexion Pharmaceuticals Annual Data
Trend Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20
Return-on-Tangible-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 11.01 10.43 1.58 33.36 6.30

Alexion Pharmaceuticals Quarterly Data
Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21
Return-on-Tangible-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 24.71 -46.30 24.39 22.10 24.82

Competitive Comparison of Alexion Pharmaceuticals's Return-on-Tangible-Asset

For the Biotechnology subindustry, Alexion Pharmaceuticals's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Alexion Pharmaceuticals's Return-on-Tangible-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Alexion Pharmaceuticals's Return-on-Tangible-Asset distribution charts can be found below:

* The bar in red indicates where Alexion Pharmaceuticals's Return-on-Tangible-Asset falls into.



Alexion Pharmaceuticals Return-on-Tangible-Asset Calculation

Alexion Pharmaceuticals's annualized Return-on-Tangible-Asset for the fiscal year that ended in Dec. 2020 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(A: Dec. 2020 )  (A: Dec. 2019 )(A: Dec. 2020 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(A: Dec. 2020 )  (A: Dec. 2019 )(A: Dec. 2020 )
=603.4/( (9162.9+10000.5)/ 2 )
=603.4/9581.7
=6.30 %

Alexion Pharmaceuticals's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2021 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(Q: Mar. 2021 )  (Q: Dec. 2020 )(Q: Mar. 2021 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(Q: Mar. 2021 )  (Q: Dec. 2020 )(Q: Mar. 2021 )
=2544/( (10000.5+10501.8)/ 2 )
=2544/10251.15
=24.82 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Mar. 2021) net income data.


Alexion Pharmaceuticals  (NAS:ALXN) Return-on-Tangible-Asset Explanation

Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.


Be Aware

Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the company’s earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a company’s tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.


Alexion Pharmaceuticals Return-on-Tangible-Asset Related Terms

Thank you for viewing the detailed overview of Alexion Pharmaceuticals's Return-on-Tangible-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Alexion Pharmaceuticals (Alexion Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
121 Seaport Boulevard, Boston, MA, USA, 02210
Alexion Pharmaceuticals specializes in developing and marketing drugs for rare, life-threatening medical conditions. Its blockbuster product, Soliris, is approved for paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), generalized myasthenia gravis (gMG), and neuromyelitis optica spectrum disorder (NMOSD). Next-generation Ultomiris is approved in PNH and aHUS. Strensiq and Kanuma target ultrarare metabolic diseases. Alexion's pipeline targets rare diseases with high unmet need in hematology, nephrology, metabolic diseases, neurology, cardiology, and other areas.
Executives
Daniel Bazarko officer: SVP, Controller, CAO C/O ALEXION PHARMACEUTICALS, INC. 121 SEAPORT BOULEVARD BOSTON MA 02210
Tanisha Carino officer: EVP & CCAO C/O ALEXION PHARMACEUTICALS, INC., 121 SEAPORT BOULEVARD, BOSTON MA 02210
Anne-marie Law officer: EVP, Chief Experience Officer C/O BAXALTA INCORPORATED, 1200 LAKESIDE DRIVE, BANNOCKBURN IL 60015
Brian Goff officer: EVP & Chief Commercial Officer C/O ALEXION PHARMACEUTICALS, INC, 100 COLLEGE STREET, NEW HAVEN CT 06510
John J Orloff officer: EVP, Research & Development C/O BAXALTA INCORPORATED 1200 LAKESIDE DRIVE BANNOCKBURN IL 60015
Indrani Lall Franchini officer: EVP, Chief Compliance Officer C/O ALEXION PHARMACEUTICALS, INC, 100 COLLEGE STREET, NEW HAVEN CT 06510
John T Mollen director 176 SOUTH STREET HOPKINTON MA 01748
David R Brennan director C/O INSMED INCORPORATED, 10 FINDERNE AVENUE, BRIDGEWATER NJ 08807
Baker Bros. Advisors (gp) Llc director 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
L.p. 667, director 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Andreas Rummelt director C/O ALEXION PHARMACEUTICALS, INC. 352 KNOTTER DRIVE CHESHIRE CT 06410
Francois Nader director 550 HILLS DRIVE, BEDMINSTER NJ 07921
Baker Brothers Life Sciences Lp director 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Deborah Dunsire director C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949
Judith A Reinsdorf director C. R. BARD, INC., 730 CENTRAL AVENUE, MURRAY HILL NJ 07974

Alexion Pharmaceuticals (Alexion Pharmaceuticals) Headlines

From GuruFocus

Alexion Pharmaceuticals Stock Appears To Be Fairly Valued

By GF Value GF Value 04-04-2021

Alexion Shareholders Approve Acquisition by AstraZeneca

By Business Wire Business Wire 05-11-2021

Alexion to Report First Quarter 2021 Results on Monday, May 3, 2021

By Business Wire Business Wire 04-20-2021